AptamiR Therapeutics
AptamiR Therapeutics is a US modular biotechnology company focused on developing targeting oligonucleotide therapeutic (ONT) drug candidates. Their mission is to develop safe, effective, and convenient therapies to address unmet medical needs, particularly in cardiometabolic disorders and ovarian cancer. They utilize a pleiotropic concept of one drug targeting multiple genes involved in complex diseases, with proven efficacy in vitro and in vivo. Their strategic focus includes advancing microRNA-based ONTs for obesity, diabetes, fatty liver disease, and ovarian cancer, aiming to help patients live healthier lives while reducing healthcare costs.
Industries
Nr. of Employees
small (1-50)
Patents
Products
miR-22-3p antagomir (PNA-backbone) — preclinical candidate
A miRNA-antagonist oligonucleotide built on a peptide nucleic acid backbone and formulated with targeting conjugates; evaluated by subcutaneous administration in rodents with demonstrated reductions in fat mass, increased energy expenditure, improved insulin sensitivity, and reduced liver steatosis in preclinical studies.
Active-targeting microRNA ONT candidates for epithelial ovarian cancer (preclinical)
MicroRNA-based oligonucleotide therapeutics engineered for active targeting to modulate multiple gene targets involved in proliferation, migration, invasion, epithelial-mesenchymal transition, and chemoresistance in epithelial ovarian cancer models.
miR-22-3p antagomir (PNA-backbone) — preclinical candidate
A miRNA-antagonist oligonucleotide built on a peptide nucleic acid backbone and formulated with targeting conjugates; evaluated by subcutaneous administration in rodents with demonstrated reductions in fat mass, increased energy expenditure, improved insulin sensitivity, and reduced liver steatosis in preclinical studies.
Active-targeting microRNA ONT candidates for epithelial ovarian cancer (preclinical)
MicroRNA-based oligonucleotide therapeutics engineered for active targeting to modulate multiple gene targets involved in proliferation, migration, invasion, epithelial-mesenchymal transition, and chemoresistance in epithelial ovarian cancer models.
Services
Internal execution of preclinical R&D programs including lead design and synthesis, in vitro assays in primary human cells, in vivo pharmacology in rodent models, NGS-based biomarker profiling, and IND-enabling planning.
Internal execution of preclinical R&D programs including lead design and synthesis, in vitro assays in primary human cells, in vivo pharmacology in rodent models, NGS-based biomarker profiling, and IND-enabling planning.
Expertise Areas
- Oligonucleotide therapeutic development
- microRNA-targeted therapeutics
- Targeted delivery of nucleic acid therapeutics
- Preclinical pharmacology and metabolic phenotyping
Key Technologies
- Peptide nucleic acid (PNA) backbone oligonucleotides
- Lipid and peptide conjugation chemistries
- Targeted uptake via fatty-acid transport mechanisms
- Primary human adipocyte cell assays
News & Updates
Global Health & Pharma Technology Award and presentation on developing active cellular targeting microRNA oligonucleotide therapeutics.
Research article by M. Thibonnier on innovative therapeutics for cardio-metabolic pandemics.
Study demonstrating the effects of microRNA-22-3p antagomirs on fat accumulation and metabolic parameters in mice.
Research on how cold exposure affects circulating microRNAs and metabolic factors, indicating potential biomarkers for cardio-metabolic disorders.
Award received by AptamiR Therapeutics for innovation in cardio-metabolic disorder therapeutics.
Global Health & Pharma Technology Award and presentation on developing active cellular targeting microRNA oligonucleotide therapeutics.
Research article by M. Thibonnier on innovative therapeutics for cardio-metabolic pandemics.
Study demonstrating the effects of microRNA-22-3p antagomirs on fat accumulation and metabolic parameters in mice.
Research on how cold exposure affects circulating microRNAs and metabolic factors, indicating potential biomarkers for cardio-metabolic disorders.
Award received by AptamiR Therapeutics for innovation in cardio-metabolic disorder therapeutics.